In a milestone that’s reverberated through Dallas, Texas, and across the global biotech world, Colossal Biosciences has done something few startups ever achieve — it’s become a decacorn, a privately held company valued at $10 billion or more, and the first in Texas to do so.
The announcement came amid a wave of fundraising and scientific progress that’s turned heads inside and outside the life sciences community. For a city better known for oil, cattle, and football, Dallas now also has a defining moment in cutting-edge genetic engineering to celebrate.
Founded only in 2021 by serial entrepreneur Ben Lamm and genetic luminary Dr. George Church, Colossal’s mission is audacious: to reverse extinction by bringing long-lost animals like the woolly mammoth, Tasmanian tiger, and dodo bird back to life using advanced gene-editing and biotech tools.
While that part of its work sometimes reads like science fiction, the company’s rapid rise to a $10.2 billion valuation reflects both investor confidence and the belief that its technologies could have far-reaching applications beyond de-extinction.
The Series C funding round that pushed Colossal past the $10 billion mark was led by TWG Global, a diversified investment firm, and brought in about $200 million — adding to the company’s total $435 million raised since launch. That figure alone signals the scale of ambition and the depth of belief from backers who see Colossal not just as a quirky experiment, but as a potential engine for transformative science.
What $10 B Really Means
View this post on Instagram
Valuation might seem like finance talk meant for boardrooms and venture capital reports, but hitting this kind of mark says something important about a business’s perceived potential. Only about 75 companies worldwide have ever reached decacorn status — firms like SpaceX, ByteDance, and OpenAI — and Colossal now ranks alongside them. That’s a remarkable feat for a startup barely out of its infancy, and even more notable for a life sciences company still years away from commercial revenue.
For Colossal’s leadership, the valuation isn’t an endpoint — it’s a tool to accelerate research. CEO Ben Lamm has said the capital will drive the company’s mission forward, helping fund everything from genome editing to artificial womb technology that could someday be used to support extinct species or bolster endangered ones. In his view, the broader vision extends well beyond any single animal project, positioning Colossal at the crossroads of biotech, conservation, and computational science.
The Science Behind the Headlines
View this post on Instagram
Most of the headlines focus on lofty, almost mythical goals — woolly mammoths tromping the Arctic tundra, or dodo birds returning to Mauritius — and while those visions are part of Colossal’s narrative, the reality on the ground is deeply rooted in real, rigorous science. The company combines powerful tools like CRISPR gene editing with computational biology and embryology to build “ancient genomes” from DNA fragments and then use those blueprints to engineer traits into living animal DNA.
One of the projects that captured global attention was the announcement of genetically engineered dire wolves — animals modeled after the long-extinct species that captivated pop culture through shows like Game of Thrones. While scientists and journalists caution that these are not true resurrected creatures but engineered proxies, the work demonstrated how far Colossal’s technologies have progressed and how they continue to push scientific boundaries.
Another area where Colossal is making incremental progress is in avian genetics. The company has developed techniques to culture primordial germ cells from species closely related to the extinct dodo, a breakthrough that could be a key step toward reviving avian species once thought lost forever. Although timelines are speculative and experts hesitate to promise specific dates for actual restoration, these advances underscore the blend of ambition and meticulous laboratory work that defines Colossal’s approach.
Beyond De-Extinction: Real-World Impact
Critics sometimes paint Colossal as chasing spectacle over substance, but the company insists its work has practical implications for conservation biology and biodiversity. Gene-editing technologies developed in pursuit of de-extinction could one day help strengthen genetic diversity in endangered animals still living today. Tools created in the lab might contribute to disease resistance, improved reproductive technologies, or even entirely new approaches to protecting at-risk populations.
Partnerships with conservation organizations and indigenous groups also highlight how the company is trying to bridge its lofty scientific goals with real-world ecosystems. These collaborations suggest that Colossal’s impact may rippl beyond purely academic achievement, influencing how species preservation is approached in an era of rapidly changing climate and widespread biodiversity loss.
What’s Next for Colossal and Dallas
As Colossal continues to grow, Dallas is increasingly in the spotlight as a biotech hub. While Boston and San Francisco have long dominated genetic research and startup culture, Colossal’s success story is putting North Texas on the map. The company’s leadership has attracted attention from cities across the U.S. offering incentives to relocate, but for now, Dallas remains home.
Looking ahead, Colossal isn’t just aiming for more funding rounds — it’s planning expansions of its scientific teams, expanding labs internationally, and building new tools that could influence fields well beyond de-extinction. Whether or not the woolly mammoth walks again, the legacy of this storied startup may lie in how it reshapes the intersection of genetics, ecology, and innovation.
A Catalyst for Change
Colossal Biosciences’ journey from a bold idea to a $10 billion decacorn is a story of ambition, science, and belief in a future where the boundaries between what is extinct and what is possible continue to blur. For Dallas and the biotech world, it’s a sign of things to come — where big ideas find big capital, and where the old frontiers of biology are being rewritten one gene at a time.